IL6 and hepatocellular carcinoma: These findings provide new insights into the oncogenic activity of PGRN in hepatocarcinogenesis in vitro and in vivo but may also reveal the IL-6/PGRN/mTOR cascade as a novel target in the treatment of HCC.